Publications by authors named "Na-qiong Wu"
Article Synopsis
- Lipoprotein(a) [Lp(a)] is recognized as a potential predictor for atherosclerotic cardiovascular disease (ASCVD), with a study involving 9944 Chinese patients revealing its association with increased cardiovascular event risk based on current risk stratification guidelines.
- Patients were categorized into very-high-risk (VHR) and non-VHR subgroups, with Lp(a) plasma levels influencing the prevalence of cardiovascular events (CVEs) observed over an average follow-up of 38.5 months.
- The results indicated that higher Lp(a) levels correlate with a significant increase in CVE risk, especially in the VHR subgroup, with adjusted hazard ratios showing a 2.18 times higher risk in the highest Lp
Article Synopsis
- This study looked at a substance called Endothelin-1 (ET-1) and how it might be linked to heart problems in people with diabetes and other blood sugar issues.
- Researchers followed nearly 8,000 patients with heart disease over a few years to see if higher levels of ET-1 could predict serious heart events, like heart attacks.
- They found that patients with diabetes or prediabetes and higher ET-1 levels were more likely to have these heart problems, suggesting ET-1 could help doctors predict risks in these patients.
Article Synopsis
- - The study investigates the clinical significance of new indices, TyAG and TyAG-BMI, which incorporate estimated average glucose into existing measures of insulin resistance (TyG and TyG-BMI) in patients with atherosclerotic cardiovascular disease (ASCVD).
- - Conducted on nearly 10,000 Chinese patients, the study analyzed cardiovascular events over 38.5 months and found that higher values of TyAG and TyAG-BMI correlated with increased cardiovascular risk factors and event rates.
- - Results indicated that TyAG and TyAG-BMI might provide improved risk prediction for cardiovascular events compared to the traditional indices, with TyAG-BMI showing the strongest predictive capability.
Article Synopsis
- - The study investigates how stress-related glycemic indicators (like admission blood glucose, stress-hyperglycemia ratio, and glycemic gap) affect cardiovascular mortality outcomes in patients over 80 years old who experienced acute myocardial infarction (AMI).
- - Researchers analyzed data from 933 elderly patients and found that higher levels of these glycemic indicators were associated with significantly increased risks of both short-term (30 days) and long-term cardiovascular mortality.
- - The results reveal a J-shaped effect for admission blood glucose and a U-shaped effect for the other two indicators, highlighting their importance in assessing the health of older adults following AMI.
Aim: No data are currently available regarding the association between Lp(a) and the cardiovascular outcomes in patients with coronary artery disease (CAD) according to their family history (FHx) of CAD. This study aimed to evaluate the significance of Lp(a) in predicting major adverse cardiovascular events (MACEs) in patients with chronic coronary syndrome (CCS) with or without FHx.
Methods: A total of 6056 patients with CCS were enrolled.
Article Synopsis
- * Misunderstandings around diagnosis and management of statin-related issues, including a lack of unified definitions, contribute to insufficient statin use and poor patient adherence.
- * This consensus aims to clarify gene polymorphisms related to statins and propose standardized diagnostic criteria and management strategies to improve their clinical application and treatment of cardiovascular disease in China.
Background: The recently introduced ultrasonic flow ratio (UFR), is a novel fast computational method to derive fractional flow reserve (FFR) from intravascular ultrasound (IVUS) images. In the present study, we evaluate the diagnostic performance of UFR in patients with intermediate left main (LM) stenosis.
Methods: This is a prospective, single center study enrolling consecutive patients with presence of intermediated LM lesions (diameter stenosis of 30%-80% by visual estimation) underwent IVUS and FFR measurement.
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups.
Expert Opin Biol Ther
March 2024
Article Synopsis
- Dyslipidemia plays a key role in atherosclerotic cardiovascular disease (ASCVD), with patients who have lipid-rich vulnerable plaques being at higher risk for complications, despite existing lipid-lowering therapies (LLTs).
- The article reviews the effectiveness of monoclonal antibody (mAb) therapies, specifically those targeting PCSK9, in managing dyslipidemia and stabilizing vulnerable plaques, alongside a brief mention of mAbs targeting other proteins like ANGPTL3.
- Expert opinions highlight that mAb treatments not only improve lipid levels but also offer additional benefits like anti-inflammatory properties and support for vascular health, making them a promising alternative for managing dyslipidemia and preventing cardiovascular events.
Article Synopsis
- * A study involved 8,263 patients with stable coronary artery disease, categorizing them by Lp(a) and Fib levels to monitor ischemic stroke occurrences over a median follow-up of 37.7 months.
- * Results showed that patients with high levels of both Lp(a) and Fib had the highest incidence of ischemic stroke, suggesting that assessing both factors together could better predict stroke risk compared to evaluating them separately.
Article Synopsis
- Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) typically need dual antiplatelet therapy for at least 1 year to reduce the risk of stent thrombosis, which is worsened by uncovered stent struts.
- This study investigates whether early use of a specific cholesterol-lowering treatment (PCSK9 monoclonal antibody) can improve the coverage of stent struts in ACS patients, compared to standard treatment, over 12 weeks.
- The research aims to provide insights that could lead to changes in treatment strategies for ACS patients, particularly the potential combination of intensive lipid-lowering therapy and shortened duration of antiplatelet therapy.
Article Synopsis
- LDL-TG (low-density lipoprotein-triglyceride) is a new lipid marker found to be connected to cardiovascular events (CVEs) in patients with chronic coronary syndrome (CCS) undergoing PCI (percutaneous coronary intervention).
- A study involving 4,415 patients investigated the association of LDL-TG and hs-CRP (high-sensitivity C-reactive protein) levels on the risk of CVEs over 7 years, revealing that higher LDL-TG concentrations correlated with more CVEs, particularly in patients with elevated hs-CRP levels.
- The findings suggest that measuring both LDL-TG and hs-CRP can help predict cardiovascular risks more effectively in patients treated with PCI, especially those with higher
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of China guidelines for lipid management is imperative, especially since the target lipid levels in the general population vary in respect to the risk of ASCVD.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to evaluate how effective sacubitril/valsartan is in lowering blood pressure in diabetes patients with primary hypertension, as well as its impact on glycolipid metabolism compared to olmesartan.
- - In the trial with 124 participants, patients taking sacubitril/valsartan experienced a significantly greater reduction in systolic blood pressure and had a higher percentage meeting their blood pressure target compared to those on olmesartan.
- - While both medications led to improvements in glucose and lipid levels, sacubitril/valsartan did not show any adverse effects and proved to be more effective in achieving blood pressure goals.
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of Chinese guideline for lipid management is imperative, especially since the target lipid levels in the general population vary in respect to the risk of ASCVD.
View Article and Find Full Text PDFBackground: There are several reports on the prevalence and characteristics of intracranial hemorrhage (ICH) following percutaneous coronary intervention (PCI), which is a rare but severe complication with high mortality. However, the clinical landscapes of computed tomography (CT)-confirmed, symptomatic ICH in hospitalized patients are not fully characterized.
Methods: Among 121,066 patients receiving PCI treatment in the Fu Wai Hospital between 2013 and 2022, there were 18 CT-defined, symptomatic patients with ICH occurring during post-PCI hospitalization.
Background: Although experimental studies have demonstrated the protective role of total bilirubin (TBil) in cardiovascular diseases, several previous clinical observations are controversial. More importantly, no data are currently available regarding the relation of TBil to major adverse cardiovascular events (MACE) in patients with previous myocardial infarction (MI).
Objectives: This study sought to explore the association between TBil and long-term clinical outcomes in patients with previous MI.
Background: Hypertension is a known risk factor for cardiovascular disease; however, its impact on clinical outcomes in patients with heterozygous familial hypercholesterolemia (HeFH) is unclear. Hence, we aimed to investigate the effects of hypertension on severity of coronary artery atherosclerosis and cardiovascular outcomes in patients with HeFH.
Methods: A total of 480 patients with clinical or molecular diagnosis of definite or probable familial hypercholesterolemia according to Dutch Lipid Clinic Network criteria (DLCN score ≥6) were included in the study.
Postprocedural cardiac troponin I (cTnI) elevation commonly occurs in patients undergoing percutaneous coronary intervention (PCI); however, its prognostic value remains controversial. This study aimed to investigate the prognostic value of peak postprocedural cTnI in cardiac patients with or without three-vessel disease (TVD) undergoing complete PCI. A total of 1237 consecutive patients (77% males, mean age 58 ± 10 years) with normal baseline cTnI levels were enrolled, 439 patients (77% males, 59 ± 10 years) with TVD, and 798 patients (77% males, 57 ± 10 years) with single- or double-vessel disease (non-TVD).
View Article and Find Full Text PDFRefractory hypercholesterolemia (RH), including homozygous familial hypercholesterolemia (HoFH) and compound heterozygous familial hypercholesterolemia, is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) despite existing cholesterol-lowering methods at maximal tolerable doses. Patients with RH have early onset and higher risk of atherosclerotic cardiovascular disease (ASCVD) under insufficient treatment. Therefore, it is urgent to seek new therapies to maintain the blood lipids in refractory hyperlipidemia at normal levels.
View Article and Find Full Text PDFBackground: The positive relationship between metabolic healthy obesity (MHO) and cardiovascular risk has been under debate in recent years. Previously, strong evidence supported the causal role of increased plasma lipoprotein(a) [Lp(a)] levels in cardiovascular disease (CVD). The current study aimed to investigate the different associations of Lp(a) and cardiovascular events (CVEs) in patients with coronary artery disease (CAD) and different metabolic phenotypes.
View Article and Find Full Text PDFAim: The aim of this study was to evaluate the relationship between renal function and low-density lipoprotein cholesterol (LDL-C) goal achievement and compare the strategy of lipid-lowering therapy (LLT) among the patients with coronary artery disease (CAD) with different renal functions.
Methods: In this study, we enrolled 933 Chinese patients with CAD from September 2020 to June 2021 admitted to the Cardiometabolic Center of Fuwai Hospital in Beijing consecutively. All individuals were divided into two groups based on their estimated glomerular filtration rate (eGFR).
Background: Currently, remnant cholesterol (RC), lipoprotein(a) [Lp(a)], and inflammation are considered the principal residual cardiovascular risk (RCVR) factors. This study sought to evaluate the combined impact of RC, Lp(a), and inflammation on prognosis of statin-treated patients with chronic coronary syndrome (CCS), which has not been investigated.
Methods: A total of 6839 patients with CCS were consecutively enrolled.
Background: Familial hypercholesterolemia (FH) is a metabolic disease in which patients are prone to develop premature atherosclerosis (AS). Sorbin and SH3 Domain Containing 2 (SORBS2) is known to play a role in coronary heart disease (CHD). However, the mechanism underlying SORBS2 involvement in the development of hypercholesterolemia remains unknown.
View Article and Find Full Text PDFArticle Synopsis
- A study involving 9,944 patients with atherosclerotic cardiovascular disease (ASCVD) aimed to understand the variability in recurrent events among them, particularly in a Chinese population.
- Researchers found that as the number of major ASCVD events increased, patients exhibited more high-risk conditions and a higher prevalence of severe coronary lesions.
- The presence of diabetes was linked to worse outcomes in patients with multiple events, highlighting the importance of tailored risk assessments rather than a one-size-fits-all approach.